|

SPADE Clinical Trial.

RECRUITINGN/ASponsored by National Cancer Center, Korea
Actively Recruiting
PhaseN/A
SponsorNational Cancer Center, Korea
Started2025-06-25
Est. completion2028-12-31
Eligibility
Age20 Years+
Healthy vol.Accepted

Summary

Purpose: This multicenter, prospective, single-arm phase 2 clinical trial aims to evaluate the safety, feasibility, and clinical outcomes of the SPADE operation (Spade-Shaped Anastomosis) in patients undergoing laparoscopic or robotic proximal gastrectomy for early gastric cancer located in the upper stomach . Background: While proximal gastrectomy (removing only the upper part of the stomach) offers nutritional advantages over total gastrectomy, it often leads to significant postoperative reflux esophagitis * The SPADE technique was developed to prevent this by creating an artificial anti-reflux mechanism (angle of His and pseudo-fornix) using double suture anchoring between the esophagus and the stomach Study Plan: Participants: The study will enroll approximately 159 patients with tumors (size ≤ 4 cm) located in the upper third of the stomach who are eligible for gastric function-preserving surgery . Intervention: All participants will undergo laparoscopic or robotic proximal gastrectomy followed by the SPADE reconstruction method . Primary Objective: The primary goal is to determine the incidence of endoscopic reflux esophagitis at one year postoperatively . Secondary Objectives: Investigators will also monitor postoperative reflux symptoms, nutritional parameters (such as weight, hemoglobin, and vitamin B12 levels), surgical complications, quality of life, and 3-year survival rates . Hypothesis: The researchers hypothesize that the SPADE operation is a safe and effective surgical approach that can provide equivalent reflux prevention (a target rate of approximately 2.9%) compared to existing complex reconstruction methods, while maintaining the benefits of preserving gastric function

Eligibility

Age: 20 Years+Healthy volunteers accepted
* Inclusion Criteria

  ① Histologically confirmed diagnosis of gastric adenocarcinoma by biopsy.
  * Adult patients aged 20 years or older.

    * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

      ④ American Society of Anesthesiologists (ASA) physical status classification of class I to III.

      ⑤ Patients who have received a full explanation of the study purpose and procedures, and voluntarily signed the informed consent form approved by the Institutional Review Board.

      ⑥ Patients eligible for proximal gastrectomy satisfying the following oncologic characteristics on preoperative evaluation:

      • Tumor location: Upper third of the stomach (High body, cardia, fundus, gastroesophageal junction \[Siewert III\])
      * Tumor size: 4 cm or less
      * Preoperative clinical stage: T1N0, T1N1, T2N0, T2N1 (any differentiation)
      * Preoperative clinical stage: T3N0, T3N1 (well or moderate differentiation)
      * Expected residual stomach: 60% or more after surgery
* Exclusion Criteria

  * Patients for whom total gastrectomy is the only appropriate treatment (e.g., presence of additional gastric cancer lesions in the distal stomach).

    ② Patients requiring concomitant resection of other organs due to other diseases.

    ③ Patients with other malignancies that may affect gastric function preservation indicators:

    • History of cancer in other organs.
    * Presence of concurrent cancer in other organs.
    * History of previous gastric resection surgery. ④ Vulnerable populations: patients lacking decision-making capacity, pregnant women, or those planning pregnancy.

Conditions9

Adenocarcinoma of the StomachCancerEarly Gastric CancerGastric Function PreservationLaparoscopic Proximal GastrectomyProximal Gastric CancerQuality of LifeReflux Esophagitis PreventionSPADE Operation

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.